Medindia

X

New Drug “Ninlaro” Receives USFDA Approval for Treating Multiple Myeloma

by Reshma Anand on  November 23, 2015 at 4:10 PM Cancer News   - G J E 4
Takeda Oncology, a drug firm has received USFDA approval for its new drug called "ninlaro" as part of the combination treatment for Multiple Myeloma.
New Drug “Ninlaro” Receives USFDA Approval for Treating Multiple Myeloma
New Drug “Ninlaro” Receives USFDA Approval for Treating Multiple Myeloma
Advertisement

The drug ixazomib marketed as ninlaro can be administered along with Celgene's Revlimid (lenalidomide) and dexamethasone to treat patients who have received at least one prior therapy. Ninlaro is a type of cancer drug called a proteasome inhibitor which works by blocking enzymes from multiple myeloma cells, hindering their ability to grow and survive.

‘Multiple Myeloma is a type of a blood cancer affecting the infection-fighting region of plasma cells which then multiply and produce abnormal proteins.’
Advertisement
Study participants received either Ninlaro in combination with lenalidomide and dexamethasone or placebo plus lenalidomide and dexamethasone. The results showed that participants taking the once-weekly regimen lived for an average of 20.6 months compared to 14.7 months in the group receiving a placebo plus Revlimid and dexamethasone, with a tolerable safety profile.

"The introduction of Ninlaro marks an important step forward, as its efficacy and safety profile - coupled with its completely oral administration - potentially can reduce some logistical burdens, and help enable patients to reap the full benefits of this sustainable therapy," noted Christophe Bianchi, president of Takeda Oncology.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All